BC
SPRY icon

Bridgefront Capital’s ARS Pharmaceuticals SPRY Stock Holding History

Bridgefront Capital’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$104K Buy
+12,926
New +$124K 0.03% 496

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bridgefront Capital's SPRY Position: Q1 2026 in Review

Bridgefront Capital opened a new position in ARS Pharmaceuticals (SPRY) in Q1 2026: 12,926 shares worth $104K. The stake represents 0.03% of the portfolio and ranks #496 among its holdings.

202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Bridgefront Capital held 12,926 shares of ARS Pharmaceuticals worth $104K as of Q1 2026.
  • ARS Pharmaceuticals was a new Bridgefront Capital position in Q1 2026.
  • ARS Pharmaceuticals made up 0.03% of Bridgefront Capital's portfolio in Q1 2026, its #496 holding.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.